Drug Approval | January 19, 2024
Lupin receives USFDA’s approval for Febuxostat Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
The product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
